AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02896855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study NCT01792089 — intervention group
Intervention type: OTHER
Intervention: fat+protein meal
Description: cream+ whey protein
Study NCT04525690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Clinicians will receive a default order upon entering the the admission order set. They will have the opportunity to opt-out and not order screening. Clinicians will receive the nudge each time they enter the admission order set for a new, eligible patient.
Study NCT02602340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation therapy
Description: Behavioral Activation therapy
Study NCT01439841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Description: The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
Study NCT01439841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fermented and subsequently heat-treated, sterile skimmed milk
Study NCT02844179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTBZ
Study NCT04846218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Study NCT04846218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Study NCT04846218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Study NCT03849794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 40 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required.
Study NCT03849794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 15 minutes in duration.
Study NCT05385029 — intervention group
Intervention type: DRUG
Intervention: Thyroxine
Description: treatment for hypothyroidism or hyperthyroidism
Study NCT04116294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted prescription
Description: The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
Study NCT01792089 — intervention group
Intervention type: OTHER
Intervention: Fat + protein + 13C fructose meal
Description: cream+ whey protein +13C fructose
Study NCT01792089 — intervention group
Intervention type: OTHER
Intervention: Fat+protein+13C fructose+glucose meal
Description: Cream + whey protein + glucose:13C fructose mixture
Study NCT01792089 — intervention group
Intervention type: OTHER
Intervention: 13C Fat + whey protein
Description: cream labelled with 13C palmitate + whey protein
Study NCT01792089 — intervention group
Intervention type: OTHER
Intervention: 13C Fat + whey protein + glucose+ glucose meal
Description: cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
Study NCT02038985 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Participants will receive ICG Dye
Description: Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
Study NCT00035165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epothilone b
Description: intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
Study NCT03582293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 500Mg Tablet
Description: orally twice daily for 28 days
Study NCT03582293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral placebo capsule two times a day for a total of 28 days
Study NCT01710826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genz-682452
Description: Capsules for oral administration.
Study NCT01710826 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the Genz-682452 capsules.
Study NCT05455970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Description: A therapeutic application of pulsed rhythmic or musical stimulation in order to improve gait or movement
Study NCT03551938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship skills session for YMSM partnered-individuals and couples
Description: Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
Study NCT02575846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Intake - Human Milk
Description: Comparing formula and human milk
Study NCT01811797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Shockwave by Renova
Study NCT02575846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enteral Intake - Formula
Description: Comparing formula and human milk
Study NCT02103439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algeron
Description: 1.5 µg/kg of body weight subcutaneously, once a week
Study NCT01811797 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment that looks, sounds and feels like the real LISW treatment.
Study NCT04523415 — intervention group
Intervention type: OTHER
Intervention: without intervention, just retrospectively review the data about patients
Description: without intervention
Study NCT01488266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5\~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
Study NCT01488266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: switching to different class of antidepressant
Description: Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
Study NCT02103439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: 1.5 µg/kg of body weight subcutaneously, once a week
Study NCT01925716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn oil
Description: corn oil 56 g/day for 21 days
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroretinography
Study NCT00389311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normosol-R
Study NCT00389311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonoxynol-9
Study NCT00389311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal instrumentation
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Contrast sensitivity test during Electroencephalography
Description: Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual simultaneity test during Electroencephalography
Description: Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
Study NCT02708628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extract of allium cepae, allantoin and heparin
Description: prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Face perception test during Electroencephalography
Description: Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CAST (cannabis abuse screening test)
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PANSS (Positive And Negative Symptoms Scale) test
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Matching to Sample (DMS) test
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spatial Working Memory (SWM) test
Study NCT01925716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: olive oil 56 g /day for 21 days
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rapid Visual Information Processing (RVP) test
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test for attentional performance (TAP) / Divided Attention
Study NCT02864680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of saliva sample
Description: In case of specific consent of participant to ancillary study, for ancillary study
Study NCT00619086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethason Helvepharm ®
Description: 8 mg Dexamethason i.v. 45 minutes prior to surgery
Study NCT00619086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml sodium chloride i.v. 45 minutes prior to surgery
Study NCT03564756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000mg Vitamin C per day
Study NCT01363609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment 12 weeks
Description: liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
Study NCT01363609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine treatment
Description: Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration \< 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
Study NCT01363609 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GLP-1 receptor antagonist
Description: Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
Study NCT01535846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious food tasting intervention
Description: Six weekly 2-hour workshops
Study NCT04559165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sericin and chitosan cream
Description: sericin and chitosan cream
Study NCT04559165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sericin and chitosan cream
Description: sericin and chitosan cream
Study NCT00931385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744
Description: BI1744 Respimat Med Dose Once Daily
Study NCT00931385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bi1744
Description: 1744 low dose
Study NCT00931385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Respimat and Foradil Placebo
Study NCT00931385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil
Description: Foradil 12 mcg twice daily and Placebo Respimat
Study NCT02594345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in vitro study
Description: Exosomes will be mixed with healthy volunteers' blood in vitro
Study NCT01418729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pravastatin
Description: Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
Study NCT01418729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
Study NCT02232139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The participants receive the pharmacological premedication before the surgery anyway
Study NCT00711867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VH2
Description: Dynatherm vitalHeat2 (VH2) temperature management system.
Study NCT00711867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger
Description: Arizant Bair Hugger temperature management system.
Study NCT03751020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW) Intervention
Description: The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.
Study NCT03751020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Affirmation (SA) Intervention
Description: The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.
Study NCT03751020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
Study NCT00828490 — intervention group
Intervention type: BEHAVIORAL
Intervention: provider feedback
Description: The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
Study NCT00828490 — intervention group
Intervention type: BEHAVIORAL
Intervention: patient intervention
Description: The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
Study NCT00828490 — intervention group
Intervention type: BEHAVIORAL
Intervention: Process-level
Description: The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
Study NCT01824069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of a suspension of adult mesenchymal stem cells derived
Description: Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
Study NCT04175873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
Study NCT04322968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
Study NCT04322968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
Study NCT01559974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to 45'000 units of Cholecalciferol per month for 3 months
Study NCT01559974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 45'000 units of cholecalciferol per month for 3 months
Study NCT00038129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nail implant
Description: Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
Study NCT03724669 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: waiting list
Description: After the study ends, they will have access to receive the educational texts and view the online lectures.
Study NCT03724669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: benzodiazepines related knowledge intervention
Description: participants receiving 11 articles pushing and 3 online lectures through the electronic interventions App, once a week, last for 3 months
Study NCT00124176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic albuterol (R+S albuterol)
Description: 20mg/hr continuous racemic albuterol
Study NCT00124176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol (R albuterol)
Description: 10mg/hr continuous nebulized levalbuterol
Study NCT01131702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Ranitidine Tablets, 300 mg
Study NCT01131702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: Ranitidine Tablets, 300 mg
Study NCT03839888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125% Atropine
Description: patients used 0.125% atropine eyedrop per night before sleep for 7 days.